AtmosR is a French biotech focused on treating rare and severe brain disorders with no existing therapies, in particular Congenital Central Hypoventilation Syndrome (CCHS), Kennedy’s disease, and Huntington’s disease. These conditions share a common feature: toxic protein aggregates in the brain. Our advanced HSP90 inhibitors penetrate the brain to eliminate these aggregates, restore normal brain function, and improve patients’ quality of life.

1
remaining day
168 investors
Investment achieved
884.135€
Target
700.000€
Invested
126.3%
126.3% INVESTED
Share this opportunity
Invest
Maturity

Prototype/preclinical

Premoney valuation

4.450.000€

Estimated exit

2029

Sector

Biotechnology

Equity offered

13.6%

Minimum investment

800€

Paris flag
Equity L
Tax deduction L
close modal
Share this opportunity

Share on your social channels

Select the social platform

Share this project on your website.

Copy and paste the following code into your content.

Invest

Overview: AtmosR

Valuation 4.450.000€
Estimated return x20
% Offered 13.6%
Estimated exit 2029

First brain-penetrant HSP90 inhibitors designed for Central Nervous System proteinopathies.

Promising preclinical results showing up to 50% reduction in toxic protein aggregates.

Increase breathing by 27% during hypercapnic challenges in CCHS mouse model.

Targeting 3 rare diseases with a single approach: clearing toxic protein aggregates in the brain.

Founded in 2019, AtmosR develops brain-penetrant drugs to treat rare and severe neurological disorders that currently lack effective treatments. The company focuses on rare genetic diseases, aiming to leverage the regulatory and market access advantages of orphan drug designation in the future to accelerate development and patient access.

PIPELINE

AtmosR was founded to address the urgent needs of families affected by CCHS, a rare and life-threatening neurological disorder that impairs respiratory function. CCHS shares a key pathological mechanism—brain protein aggregation—with other severe neurological diseases that also lack effective treatments. This led AtmosR to develop therapies targeting three debilitating conditions:

  • Central Congenital Hypoventilation Syndrome (CCHS): A neurodevelopmental disorder leading to widespread autonomic system impairment, including life-threatening respiratory problems.
  • Kennedy’s disease (Spinal and Bulbar Muscular Atrophy): A neuromuscular degenerative disorder causing muscle weakness, difficulty speaking, and trouble swallowing.
  • Huntington’s disease: A neurodegenerative disorder characterized by severe motor dysfunction (Huntington’s chorea), cognitive decline, and psychiatric symptoms.

TECHNOLOGY

AtmosR has developed a completely new chemical series of brain penetrant 3rd generation HSP90 inhibitors, capable of destroying these aggregates and restoring the deficient mechanisms. AtmosR technology intellectual property is secured by a composition of matter patent, with worldwide freedom to operate.

The company lead compound is able to correct disease-driving parameters in animal model of the targeted pathologies. This data emerged from collaborations with key opinion leaders from renowned organizations such as Sorbonne Université in Paris, Children’s Hospital of Chicago, Nagoya University, and the Institut de Neurociències at the Universitat de Barcelona.

AMBITION

AtmosR was founded by a multi-disciplinary team with expertise in both business management and drug development, with a particular focus on rare diseases. We aim to provide an effective, long-lasting drug solution to treat patients suffering from serious neurological pathologies with no treatment. We plan on entering the clinic in 2027, and will leverage the current fundraising round to consolidate the in vivo proof of concept data package, including derisking of safety and CMC, in order to be ready to start preclinical regulatory studies by the end of 2025.

Why is Capital Cell investing in this company?

AtmosR is at the forefront of developing a new generation of protein inhibitors capable of crossing the blood-brain barrier to treat central nervous system diseases caused by protein aggregation. This represents a major scientific breakthrough, as protein aggregation is at the core of many neurodegenerative diseases.

AtmosR's lead candidate has demonstrated its ability to act on the underlying causes of these diseases, reducing protein aggregation by up to 50% in three targeted pathologies. Furthermore, in animal models of Congenital Central Hypoventilation Syndrome (CCHS), the compound significantly improved breathing, highlighting its therapeutic potential.

To date, no effective curative treatment exists for these devastating conditions, and current solutions only manage symptoms without halting disease progression. By directly targeting the underlying mechanisms, AtmosR addresses a critical medical need and could qualify for orphan drug designation. This status would provide accelerated approval processes, regulatory support, and market exclusivity, enabling faster treatment development and patient access.

Additionally, AtmosR's technology is backed by strong intellectual property, protected by patents covering its innovative approach.

With the goal of entering clinical trials by 2027, AtmosR is seeking funding to advance to the preclinical phase, ensuring the continued development of its treatment and offering new hope to patients suffering from rare and severe neurological diseases.

Minimum investment: 800€
Type of exit expected: Licencing or M&A
Drag-along rights
Tag-along rights
Tax deductions
Subscribing to the capital of a company, such as a JEIR, entitles the investor to a reduction in income tax (IR-PME) equivalent to 50% of the amount invested, provided certain conditions are met. The subscriber must be a natural person, i.e. an individual or sole trader, resident in France for tax purposes, and must undertake to hold the securities received in exchange for the subscription (company shares or stocks) for a minimum period of five years. The amount of payments taken into account when calculating this tax reduction is limited to €50,000 for a single, widowed or divorced person, and €100,000 for a married or civil union couple subject to joint taxation. For more information, visit entreprendre.service-public.fr.
Main risks

Despite the promising results obtained in animal models, the transition from the preclinical to the clinical phase remains a complex process. Adjustments will be necessary to refine toxicity assessment, optimize the administration regimen, and determine long-term effects, particularly in the context of chronic treatment in children. Moreover, while these rare neurological diseases represent an unmet medical need, market access and adoption may require lengthy and complex negotiations. Treatment costs, integration into healthcare systems, and gradual adoption by clinicians will be key factors in ensuring the commercial success of AtmosR's solution.

Register now to see the full pitch of AtmosR.

Developing targeted treatments for rare neurological disorders caused by toxic protein aggregates with no current therapies available
Register with your email

Already have an account? Please login here .

close modal
INVEST
approved icon Approved
regulated icon Regulated
secured icon Secure
WHAT TYPE OF INVESTOR ARE YOU?
PLEASE, TAKE THE INVESTOR TEST

In order to protect inexperienced investors, the European law establishes an initial classification of types of experienced and inexperienced investors. We will ask you a few brief questions to find out what type of investor you are.

If you do not take the test and we cannot categorize you, we must apply a maximum limit of 1,000 euros per project.

We are obliged to remind you and confirm with each investment that you accept the risks of investing in unlisted companies. Learn more

TAKE THE TEST brain-icon
Applicable discounts
Base price
28,04€ /share
Volume discount
7.5% Price 25,94€
As of 5.000,00€
Amount to be invested
€
The minimum investment is 800,00€
Summary of your investment
The price that applies to you is:
/share
Final investment
0,00 €
0 shares at €

*Make sure you are fully aware of the risks of investing in unlisted companies. Learn more